We investigate the physicochemical characteristics of celecoxib (CEL) entrapped within particles of an oxidized porous silicon matrix (pSiox); determine the oral dose response of CEL compared to pure drug and innovator formulation; develop in vivo-in vitro correlation (IVIVC). CEL was loaded into a pSiox matrix by solvent partitioning, with the physical state of the CEL characterized by FTIR, DSC, TGA and XRD, and correlated with in vitro dissolution behavior. Single dose pharmacokinetic parameters of orally dosed CEL were determined in fasted rats for aqueous suspensions of pure CEL, Celebrex and CEL-pSiox microparticles. Physicochemical testing of CEL-pSiox formulation confirmed the entrapment of CEL within porous nanostructure in an amorphous or non-crystalline form. CEL-pSiox demonstrated superior pharmacokinetics compared with CEL particles or Celebrex , i.e. increased absolute bioavailability (96.2% vs. 65.2% vs. 88.1%), increased C (0.91 ± 0.09 µg/mL vs. 0.50 ± 0.16 µg/mL vs. 0.73 ± 0.23 µg/mL) and reduced T (1.0 ± 0.0 h vs. 2.8 ± 0.8 h vs. 3.4 ± 1.0 h). Single point correlation was established between in vitro dissolution efficiency (% DE) and in vivo absolute bioavailability or C . Porous silicon microparticles can be formulated as an effective orally dosed solid dispersion preparation for celecoxib. 
Introduction
Many existing and emerging active pharmaceutical ingredients do not reach their designed efficacy due to their hydrophobic nature and poor aqueous solubility, hence resulting in low systematic bioavailability when dosed orally. One example is celecoxib (CEL) (i.e. 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulphonamide ( Fig. 1) ), a selective inhibitor of cyclooxygenase-2 (COX-2) approved by FDA in 1998 for treatment of osteoarthritis and rheumatoid arthritis. properties and blend uniformity [6] . Numerous formulations have been reported for improving the physical properties, solubility and bioavailability of CEL; these include colloidal/nanomedicine, solid state/solid dispersion, and porous particle approaches [7] [8] [9] [10] [11] [12] [13] [14] . With respect to colloidal/nanomedicine approaches, inclusion complex formation with cyclodextrins (CDs) is an established approach for encapsulation and delivery of insoluble drugs, and β-CDs complexes with CEL have resulted in enhanced solubility and dissolution rates [7, 8] . Nonionic microemulsions. [9] and self-microemulsifying drug delivery systems (SMEDDS). [10] are also reported to improve the solubility of CEL and facilitate a 130% relative bioavailability in human volunteers. More recently, a silica-lipid hybrid (SLH) system has been reported to enhance CEL's bioavailability in comparison to drug particle and emulsion formulations in both rodent [11, 12] and dog [13, 14] models. The SLH system combines the drug solubilizing attributes of both lipid carriers and porous silica. In considering solid state approaches, CEL solvates [4] and porous CEL powders obtained from melt sonocrystallisation [15] are examples that show better solubility and flow property compared to the crystalline form. Solid dispersion approaches have become popular for bioavailability enhancement of poorly soluble drugs. Typically, water soluble polymers, such as polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG), are used for solid dispersions and prepared either by melting or solvent evaporation (e.g. spray drying) methods. Within solid dispersions, the drug is molecularly dispersed or exists as an amorphous form; thus drug dissolution kinetics is enhanced once the water-soluble carrier disintegrates in gastrointestinal (GI) fluids [16] . For example, molecular dispersions have been prepared by incorporating CEL into poly-(vinylpyrrolidone) (PVP), with ∼20% CEL able to be incorporated in a stable amorphous form [17, 18] . Mesoporous materials, most notably silica materials such as MCM and SBA (pore sizes 2 -5 nm), are also proposed as attractive solid dosage forms for poorly soluble drugs. Their high surface areas enable surface stabilization of molecular or amorphous drugs at high loading levels and enhance drug dissolution [19, 20] . Unlike polymeric materials, these inorganic porous materials are considered inert in gastrointestinal fluids and provide an alternative mechanism for enhancing drug solublization and absorption. Recently, Peng et al. reported both improved dissolution and bioavailability of CEL loaded into fibrous ordered mesoporous carbon (FOMC) [21] .
Porous silicon (pSi), fabricated by electrochemical etching of silicon wafers, is an emerging material for biomedical use and drug delivery applications [22, 23] . It offers a number of attractive features, some equivalent (e.g. high loading capabilities and biocompatibility) and some complementary to mesoporous silica [24, 25] . Pore size, shape and chemistry of pSi are arguably more controllable than for porous silica, while the native pSi possesses a highly reactive Si-H (y=1 -3) surface, which is responsible for the pSi degradation/dissolution and corresponding excellent biocompatibility [25, 26] . To passivate the Si-H surface, numerous well established methods are available, including; thermal oxidation [27] [28] [29] , thermal carbonization [30, 31] , hydrosilylation [32] and PEGylation [33] . These well-established organosilicon chemistries can be used for surface modification, providing a range of tailored surface chemistries for loading of therapeutic molecules, including water soluble [34] and insoluble [20, 35] drugs, while recent attention has focused on the delivery of peptide and protein based therapeutics [36] [37] [38] [39] [40] [41] [42] . pSi is considered a more active surface, with both degradation/dissolution controlled release and pore release mechanisms. It has therefore been explored for diversified delivery routes such as oral administration [20, 43] , transdermal [44] , implantation [45] as well as time-controlled and bio-triggered delivery device [46] . Previously, we have reported on the use of pSiox for the delivery of indomethacin (IMC), where we demonstrated control over the IMC solid state in a stable amorphous form as well as improved in vitro dissolution and in vivo performance in a fasted rat model compared to the pure drug or the commercially available product (Indocid ) [20] . We now extend this study by considering CEL, a significantly more challenging BCS class II compound to formulate, being a weaker acid than IMC (pKa 11.1 vs 4.5, respectively) resulting in a significantly reduced solubility under physiological conditions.
In the present study we aim to develop a non-crystalline solid state formulation of CEL using thermally oxidized pSi microparticles as a carrier. The solid state properties of CEL-pSiox solid dispersions were probed by Fourier transform infrared spectroscopy (FTIR), X-ray powder diffraction (XPRD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). We then focus on correlating in vitro dissolution with orally dosed in vivo pharmacokinetics performance in a fasted rat model; in particular, the performance of CEL-pSiox is quantitatively compared with CEL powder and the commercially available Celebrex formulation.
Materials and methods

Materials
Porous silicon (pSi) microparticles were prepared by electrochemical anodization as reported previously [22] . In brief, p + (0.005 -0.020 Ωcm) silicon wafers were electrochemically anodized to obtain a pSi layer having the designated morphology, i.e. ∼70% porosity, specific surface area (SSA) = 310.2 m 2 /g and total pore volume (TPV) = 0.955 cm 3 /g. The pSi layer was separated from the substrate and subsequently ground by jet milling. The powder was further classified to microparticles with D 50 = 13.4 µm, as shown in Figure S1 (supporting information). The pSi microparticles were thermally oxidized by heating in air at 600
• C for 1 in a clean furnace with temperature variation <± 5
CEL (99.0%) was purchased from ChemPacific (Canada). Tween-80 (Polyoxyethylene sorbitan monooleate, HLB 15) was supplied by Chem Supply Pty Australia. All other chemicals were of analytical grade and used as received. High purity (Milli-Q, resistivity >18.2 MΩcm) water was used throughout the study.
Amorphous CEL was prepared as previously reported in literature [47] , whereby ∼1 g of crystalline drug was placed in a nickel crucible and then heated to ∼185
• C for ∼5 min until molten. The molten drug was then quenched in liquid nitrogen. The resulting glass-like drug was gently ground into a fine powder using a mortar and pestle, prior to analysis.
CEL loading of pSiox
Thermally oxidised pSi (pSiox) microparticles were loaded with CEL using a solvent immersion, partitioning and evaporation approach. pSiox microparticles were immersed in a chloroform solution of CEL (10 mg/mL) for 6 h with gentle shaking at 25
• C. After incubation, the pSiox microparticles were collected via vacuum filtration through a glass fiber membrane and then air dried at 60
• C for 2 h. The CEL loaded pSiox microparticles are subsequently labeled as CEL-pSiox. The CEL loading level was determined by an ethanol extraction process followed by HPLC analysis. Based on 5 independent loading studies and analyses, the CEL content was determined to be 5.01 ± 0.74 wt %. A range of physicochemical methods were used to monitor the physical state of loaded drug.
Transmission FTIR
FTIR spectra of compressed KBr discs (containing 1% sample) were recorded using a Nicolet Magna-IR 750™ FTIR spectrometer equipped with a liquid nitrogen cooled mercury-cadmium-telluride (MCT) detector.
X-ray powder diffraction (XRD)
Powder XRD spectra of CEL-pSiox formulation were recorded using a Philips X-ray diffractometer (Philips, Holland) with monochromatic Cu Kα (λ = 1.7902 Å) radiation generated by a power source of 45 kV and taken between 2θrange of 10 -50
• with a scan rate of 0.5
• /min and a step size of 0.02
Differential scanning calorimetry (DSC)
DSC of CEL-pSiox formulations were performed on a TA Modulated DSC 2920 (TA Instruments). The sample (5 ± 1 mg) was cramped in aluminum pan before exposure to heating at a rate of 5 
Thermogravimetric analysis (TGA)
A Hi-Res modulated TGA (TA Instruments, USA) was used to obtain TGA thermograms of CEL loaded pSiox. Approximately 10 mg of sample was place in a platinum crucible at a heating rate of 10
• C/min from 25 to 800
• C under nitrogen purging.
HPLC analysis
CEL content in blood plasma was assayed using a Shimadzu HPLC system which consists of a system controller (SCL-10A), an isocratic pump (LC-10AT), an auto sample injector (SIL-10A), and a UV-VIS detector (SPD-10A) with wavelength set at 254 nm. An Alltech Lichrospher 100 RP-18 (4.6 × 250 mm, 5 µm) column was connected. The mobile phase was a mixture of acetonitrile and water (65:35) containing 0.2% v/v of glacial acetic acid, and was delivered at ambient temperature at an isocratic flow rate of 1.0 mL/min. The sample injection volume was 20 µL. The limit of detection (LOD) and the limit of quantification (LOQ) were 0.01 and 0.05 µg/mL, respectively. The intra-and inter-day assay precision was assessed by coefficient of variance (< 3 % and < 7 %, respectively) and the accuracy was assessed as percentage bias (< 5 %). The obtained calibration curve of chromatographic peak areas versus CEL concentrations over the range of 0.2 -20.0 µg/mL and 0.05 -10 µg/mL has a linear regression coefficient R 2 = 0.998. CEL concentrations from CEL-pSiox extracts and in vitro dissolution studies were determined using a modified as-says HPLC method. That is, a Phenomenex (Luna, C18, 5 µm, 150 × 4.6 mm) column was used and the mobile phase was a mixture of acetonitrile, 0.01 M potassium phosphate monobasic solution (pH 3.5) and methanol (50:40:10, v/v) containing 0.1 v/v % of triethylamine to achieve a suitable retention time. Other conditions were same as the above HPLC method.
In vitro dissolution
In vitro dissolution was performed using a Vankel (VK 6010) dissolution test station with USP apparatus II (paddles) operating at a rotation speed of 100 rpm. 500 ml of 0.05 M phosphate buffer pH 7.2 was degassed by filtration through a 0.45 membrane under vacuum and was maintained thermostatically at 37 ± 0.5
• C throughout the entire study. The amount of sample (equivalent to ∼15 mg of the pure CEL) was pre-dispersed into a small aliquot of dissolution medium and then immediately transferred into dissolution flask. An aliquot of solution was withdrawn and replaced by an equal volume of the fresh medium at the designated time intervals, and immediately filtered through an 0.2 µm syringe filter (Acrodisc ) to remove pSiox microparticles. No CEL adsorption onto the membrane was observed, based on the LOQ of the HPLC method used in this study. The filtrate was diluted suitably with mobile phase solution prior to HPLC analysis. In a second series of in vitro tests, the sample mass was reduced to in equivalent to ∼2.5 mg of CEL; while, the dissolution media was modified to contain 0.2 % w/v Tween-80 to determine the CEL release kinetics under sink conditions. All assays were run in triplicate.
In vivo pharmacokinetics
In vivo experiments were performed on Sprague-Dawley rats weighing 330 ± 30 g, housed in a temperaturecontrolled room with access to water and food ad libitum. All of the experiments were conducted in compliance with directive 2010/63/EU of the European Parliament for the welfare of experimental animals and with the approval of the Animal Ethics Committee, Institute of Medical and Veterinary Science (Adelaide, Australia). Groups of 4 male rats were used for each PK study. One group was dosed intravenously with 5 mg/kg CEL in PEG 400/saline (2:1v/v), while the other two groups were orally administered with a single dose of either formulation with equivalent CEL, by oral gavage under light inhaled anesthesia (isoflurane). Three oral CEL formulations were investigated: free crystalline CEL particles, the powder of Celebrex capsules and CEL-pSiox powder (hydroxylpropymethylcellulose (HPMC) solution (0.7% w/v) was used as a suspending agent). The rats were cannulated in the right jugular vein under inhaled anesthesia, and allowed to recover. The cannulated rats were fasted overnight (14 ± 1 h) prior to each oral dosing and were given access to food 4 h post-dose, but water was accessible at all time. Blood samples (0.2 mL) were collected from the jugular vein at designated time intervals and the cannula was flushed with an equal volume of heparinised normal saline (50 units/5 mL) to prevent blood clotting. The collected blood samples were centrifuged at 9400 g for 5 min. 100 µL aliquots of plasma were vortex-mixed with 100 µL of acetonitrile and centrifuged at 3500 g for 10 min to remove proteins prior to HPLC analysis as described above. obtained were used to estimate the absolute bioavailability (F) according to Eq. 1:
Statistical analysis
The pharmacokinetic data from the different formulations were analysed statistically by one-way analysis variance (one-way ANOVA) with a Least Significant Difference (LSD) post-hoc test using SPSS 15.0 for Windows (SPSS Inc.). For all tests, the level of significance was set at 0.05.
Results
Solid state characterization of celecoxib loaded porous silicon
FTIR is well established for investigating the molecular conformation of pharmaceutical solids [48] as well as for characterizing the internal and external surface of pSiox, [38] thus it is particularly suitable for studying of physical state of CEL loaded within the pSiox matrix. FTIR absorbance spectra of crystalline and amorphous CEL, CEL-pSiox and pSiox microparticles are presented in Fig. 2 . For crystalline CEL, the N-H stretching vibration of the -SO 2 NH 2 group presents as a doublet at 3338 and 3232 cm and 1273 cm −1 [49] . Amorphous CEL exhibits a broad and diffused N-H stretching vibration, while the asymmetric S=O stretching is shifted to a lower wavenumber position (1340 cm ) of pSiox (Fig. 2b) , CEL absorbances in the range of 1600 -1350 cm and tentatively assigned to C-H bending of the benzene and pyrazol rings, resemble those from amorphous CEL. In addition, the decreased intensity of O-H stretching at 3745 cm −1 due to the isolated surface hydroxyl group of pSiox upon CEL loading is indicative of hydrogen bonding between the surface hydroxyl group and CEL molecules [50] .
X-ray diffraction is a primary tool for determination crystallinity of pharmaceutical solids [51] and has been employed here for characterizing the form of CEL in the porous silicon formulation (see Fig. 3 ). Crystalline CEL exhibits a number of characteristic diffraction peaks, particularly at 18.8 and 25.1
• /2θ and consistent with a previous report [15] . The slight difference in peak position and intensity can be attributed by crystal size [52] . The diffractogram of the CEL loaded pSiox shows absence of all characteristic peaks of crystalline CEL, except a broad single peak at 32.9
• /2θ, identical to the one presented in the diffractogram of pSiox microparticles. This diffraction peak was previously assigned to the diffused Si(111) diffraction of the oxidized pSiox lattice [53] . The absence of crystalline diffraction peaks suggests that the encapsulated CEL existed either as non-crystalline or amorphous form. DSC was also applied to characterize the form of CEL when loaded in the pSiox matrix, see Fig. 4 . Crystalline CEL shows a single endothermic event due to melting at 163. • C was observed and is in agreement with the literature [4] . DSC thermograms of a physical mixture of CEL and pSiox (containing an equivalent quantity the CEL to the loaded samples) clearly showed an endothermic peak corresponding to T , i.e. the detection limit for crystalline material is significantly lower than the levels in the samples under investigation. In contrast, no endothermic DSC peak is observed for CEL loaded pSiox, confirming the encapsulated CEL is non-crystalline, i.e. either amorphous or a molecular adsorbed form. Derivative TGA thermograms (Fig. 5) of crystalline CEL show a sharp weight-loss peak in the temperature range 276 -357
• C, which corresponds to thermal degradation of the CEL molecule. Interestingly, the equivalent thermal degradation peak for CEL loaded pSiox is observed over a wider temperature range, i.e. 280 to 511
• C, attributed to a combination of the confinement of the CEL within the pSiox porous matrix, as well as the CEL-pSiox surface interaction. The TGA of pSiox microparticles in this temperature range show no equivalent weight changes. This observation is consistent with thermal protection and diffusional constraint in the confined space of the pSi matrix [54] . 
In vitro dissolution
The dissolution profiles of CEL-pSiox, Celebrex and bulk crystalline CEL under non-sink conditions (sample masses were equivalent to 30 mg/L of CEL in the dissolution media) are presented in Fig. 6a . CEL-pSiox exhibited rapid dissolution in the initial 30 min with a maximum of concentration of 7.3 µg/mL (i.e. 30.5 % CEL dissolution); this is higher than the previously reported solubility value of amorphous CEL [2, 55] . The observed supersaturated state of CEL declines only slightly over a 4 hour period. In contrast, crystalline CEL and Celebrex displayed significantly reduced dissolution kinetics, with maximum CEL concentrations of 1.1 and 2.8 µg/mL, respectively. Additional dissolution studies were performed in phosphate buffer solution pH 7.2 containing Tween 80 (0.2 % w/v) for samples containing 2.5 mg of CEL in the 500 mL of medium, i.e. approximately sink conditions (see Fig. 6b ). A similar trend was observed, i.e. the rate and extent of dissolution followed the order: CEL-pSiox > Celebrex > CEL. Interestingly, the initial fast dissolution from the CEL-pSiox (i.e. 86 % in first 40 min) was independent of the presence of Tween 80, whereas the remaining 10 -15% of encapsulated CEL was released more effectively in the presence of Tween 80.In vivo pharmacokinetics The mean plasma concentration-time curves obtained from the fasted rat model following oral administration of suspensions of CEL-pSiox, Celebrex and bulk CEL, respectively, along with intravenous dosing of CEL are presented in Fig. 7 , while the corresponding pharmacokinetics data are given in Table 1 . Oral dosing of CEL powder resulted in a broad plasma concentration versus time curve with a maximum (C ) of 0.50 ± 0.16 µg/ml at 3.4 ± 1.0 h (T ); this indicates weak and heterogeneous absorption of CEL due to its low solubility in the GI fluid and fast tissue distribution [56] Administration of Celebrex resulted in a moderate increase of C (0.73 ± 0.23 µg/mL) and a reduced T (2.8 ± 0.8 h) compared to the CEL suspension. The value of T is in close agreement to that obtained for the fasted human volunteers (2.4 h) [2] Oral dosing of the CEL loaded pSiox showed superior pharmacokinetic performance as indicated by the further increased C (0.91 ± 0.09 µg/mL) and significantly reduced T (1.0 ± 0.01 h). The absolute bioavailability (F %) calculated from the systemic exposure i.e. area under curve (AUC 0−12 ) of the samples relative to that of intravenous administration of CEL is 96 % ± 3.5 for the CEL loaded pSiox, which is superior to 88.1 % ± 9.4 and 66.3 % ± 3.3 for Celebrex and CEL suspension, respectively. The value of F % obtained for CEL suspension is close to that previously reported on dog subjects [56] Statistical analysis showed that the pharmacokinetic parameters, i.e. C , T and F % obtained for CEL loaded pSiox are significantly higher compared to those from the other two formulations (p<0.05).
Discussion
Physicochemical properties of CEL
Solid state characterisation of the CEL-pSiox matrix provides evidence of both entrapment of the CEL within the pSi matrix, as evidenced by the prolonged decomposition observed using TGA, as well as the stabilization of the CEL in a amorphous or non-crystalline form. This is attributed to diffusional constraints restricting CEL crystal formation within the geometric confines of the pSi pores [57] . This phenomena has previously been reported for ibuprofen condensation within mesoporous silica [58] , The incorporated ibuprofen molecules on the mesoporous silica were found to appear as viscous liquid in the nanosized pore channels since the molecules formed dimers rather than a highly ordered crystalline structure [59] .
In vitro release of encapsulated CEL
The Noyes-Whitney equation was used to model the CEL dissolution [60] ;
where S is the saturation or apparent solubility, is a constant that relates to the hydrodynamics of the dissolution cell, A is the surface area and C is the concentration of the solute in the medium. When C is equal to zero at t 0 , the initial dissolution rate is directly proportional to the apparent solubility. Under non-sink conditions, dissolution tests can be used to evaluate the solubility or apparent solubility of poorly soluble compounds in the early stages of their dissolution, prior to equilibrium being achieved [61] . In the present study, an apparent solubility of 7.3 µg/mL was observed for CEL, which was higher than has been previously reported for various physical states of CEL [2, 15, 55] , including 6.2 µg/mL for amorphous CEL [15] . The hydrophilic surface and large specific surface area of the pSiox matrix (∼310 m 2 /g) [28, 29] also play important roles in the enhanced CEL dissolution. The excellent physicochemical stability of pSiox, results in a significantly reduced Si dissolution rate compared to unoxidized pSi (e.g. see ref [62] for further reading in this area). Therefore, it is proposed that CEL release occurs by diffusion from the pores, rather than via a matrix erosion type mechanism. A similar release mechanism has been observed for indomethacin from pSiox [20] , and for various drugs (e.g. ibuprofen) releasing from mesoporous silica [19, 63] . Tween 80 (1% w/v) has previously been used to achieve sink conditions in media simulating the gastrointestinal (GI) tract for dissolution studies of several different CEL formulations [64] . In the present study, a lower Tween 80 concentration (0.2 % w/v) was used with the intention of achieving better in vitro and in vivo correlation, while remaining significantly greater than the critical micelle concentration (CMC) (0.005% w/v). Tween 80 may also interact with the pSiox surface and facilitate a specific CEL release mechanism by "surface displacement", whereby the Tween 80 displace surface adsorbed CEL. Additional CEL dissolution studies under sink conditions were also performed in the absence of Tween 80, i.e. using reduced sample quantities. The time taken for 85% dissolution (t 85% ) from CEL-pSiox was less than 20 min (for dissolution media both with and without Tween 80), in compliance with the US-FDA guidance for immediate release products (i.e. t 85% < 30 min) [65, 66] . The dissolution medium containing Tween 80 is considered to be more relevant to physiological conditions, given the role of naturally occurring and solubilising surfactants such as bile acids, bile salts and lecithin within the GI tract [67] . The presence of surfactants in the dissolution medium has previously been demonstrated to influence drug release from a porous matrix, particularly where the pore size was less than 20 nm [68] . However, in the current study no significant difference in dissolution was observed with or without Tween 80. A similarity factor ( 2 ) has been defined to assess the similarity of dissolution profiles, as used by the Center Drug Evaluation and Research (CDER, FDA), and can be determined using Eq. 3; [69] 
where is the sampling number, R and T are the percent of reference and test products dissolved at each time point j. The 2 values obtained for CEL dissolution in the presence and absence of Tween 80 for the first 60 minutes of dissolution ranged from 81 to 53, indicating that the two dissolution profiles are highly similar. At longer times, however, the release of the remaining CEL was more significantly enhanced by the presence of the Tween 80 (Fig. 6b) . Tween 80 is considered to facilitate the release of the remaining CEL inside the pore channels through a surface desorption and solubilisation processes.
In vivo absorption of CEL-pSiox
The significantly reduced T for the porous silicon carrier compared with Celebrex is of clinical significance for NSAID's delivery, as it ensures a fast onset of action. The T value of 1.0 h for the CEL-pSiox solid dosage is comparable to 0.6 h for a solution formulation in dogs [2] and 1.5 h for a CEL self-microemulsifying drug delivery system (SMEDDS) in humans [10] . The fast in vivo absorption from CEL loaded pSiox is considered to be due to a combination of fast release of the molecular form, a short gastric transit time due to the higher specific gravity of pSiox compared to the normal solid dosage forms and the potential for pSiox to enhance drug permeability. This is in good agreement with previously reported enhanced drug permeability observed across model Caco-2 monolayers with the use of pSiox as the delivery vehicle [70, 71] . Interestingly, Celebrex contains surfactants and other excipients for enhancing disintegration, dispersion and dissolution, and also potentially increasing permeability, whereas the faster acting and more bioavailable CELpSiox is surfactant free, which is advantageous when considering reducing toxicity and irritation to the GI tract. The performance of CEL-pSiox is comparable to the enhanced oral absorption of the poorly water-soluble drug itraconazole using a mesoporous silica carrier [72] and for indomethacin dosed in pSiox microparticles (18).
In vitro -in vivo correlation (IVIVC)
Based on the findings of Khan [73] , we have employed the dissolution efficiency (%D.E.) to establish an IVIVC in the current study, i.e.:
where 0 × is the area under the dissolution curve up to time, ; and 100 × is the area of the rectangle described by 100% dissolution over the same time. Fig. 8 demonstrates reasonable correlations between %DE (at 180 and 240 mins) and F (%) and %DE and C for the three CEL formulations. This correlation is in agreement with that reported for silica-lipid hybrid microparticle formulations of CEL [11] , even though different solubilisation and delivery mechanisms are in effect. To establish a point-to-point IVIVC we have used the Wagner-Nelson method to extract the in vivo absorption of CEL from the PK data; this is based on a one-compartment model with first-order elimination, i.e. [74] : was obtained using the final time point at 24 h instead of 10 h, since the literature shows that CEL plasma levels are detectable at this time after intravenous administration to rats at 1 mg/kg CEL (5-times less than the dose used in the current investigation) [75] . Based on this deconvolution approach, the in vivo absorption profiles for the 3 CEL formulations are presented in Fig. 9a . Due to intrinsic difference between in vitro dissolution and in vivo absorption, it is necessary to adjust the time scale to facilitate a direct point-to-point comparison between these two processes. A time scale factor α = 3 was estimated from linear fitting of the data of both the in vitro release and the in vivo plasma concentration-time profiles using the Weibull function (refer to the supporting data, Figure S2 and Table S1 ). Plots of in vivo absorption versus the in vitro release at corresponding time points for the 3 CEL formulations are presented in Fig. 9b . For both powdered CEL and Celebrex , a linear correlation between in vitro release and in vivo absorption was observed from time zero to T . For CEL-pSiox, only three time points were included because >80 % CEL was released within the initial 5 min. In contrast to our previous study on indomethacin [20] , the correlation for CEL does not go through the origin. The Wagner-Nelson approach is particularly suitable when the limiting factor for drug absorption is well de-
Fig 9.
In vivo absorption profiles generated using the Wagner-Nelson method for CEL loaded pSiox ( ), Celebrex (♦) and CEL suspension ( ) from the corresponding mean plasma concentration versus time profiles.
fined and drug release occurs from an extended release dosage form. For immediate release dosage forms, however, it usually fails because drug absorption does not only depend on drug dissolution, but also on gastric emptying and intestinal residence time [76] . Here, the limiting factor to CEL absorption was clearly defined as poor dissolution. The fast in vitro dissolution of CEL from the pSiox matrix suggests that dissolved CEL is rapidly available in the intestinal tract, ensuring fast absorption even if its intestinal residence time is limited. Previously, a high level IVIVC has only been demonstrated for water soluble drugs when apparatus I or II methods and phosphate buffer solutions were used in dissolution studies. For example, oral solid dosage controlled release formulations of theophylline [77] and a modified-release levosimendan formulation [78] . For an immediate release formulation, in particular of BCS class II drugs, Dressman et al. [79] suggested that in vivo absorption should be predictable if the GI tract environment can be reconstructed in vitro. This includes use of biorelevant media, such as SGF, milk, fed-and fastedsimulated intestinal fluid (FeSSIF and FASSIF, respectively) for mimicking fasted and fed states in the stomach and small intestine. The use of the USP II dissolution apparatus with biorelevant media has successfully predicted the in vivo performance of several poorly soluble drugs, e.g. danazol, ketoconazole and atovaquone. Since CEL is insoluble in aqueous medium within the physiological pH range, dissolution study of its commercial formulation is recommended to be performed in tribasic sodium phosphate solution (pH 12) with 1 % SDS for tier 1 and the simulated gastric fluid including pepsin then diluted NaOH solution (pH 12) for tier 2. These conditions significantly deviate from biological conditions [79] . In this present study, we successfully demonstrated that IVIVC for CEL using a simple in vitro dissolution method, i.e. an apparatus II and phosphate buffer solution at pH 7.2 containing 2 mM Tween 80 as medium and for a small sample mass (i.e. 2.5 mg of pure CEL). This confirms that the improved dissolution is the major factor contributing to the enhanced in vivo absorption for the CEL-pSiox formulation.
Conclusion
This study has demonstrated that the potential of the oxidized pSi microparticles being successfully developed as a solid dispersion of poorly water-soluble drug, celecoxib. In vitro solubility and rate of dissolution of CEL have been significantly improved due to molecularly dispersed state of CEL and large hydrophilic surface of pSiox matrices. As the consequence, this CEL-pSiox solid dispersion produced a superior in vivo oral absorption (96 % absolute bioavailability) with dramatically reduced T compared to Celebrex and free CEL, which is ideal for an immediate release formulation. 
